Northwest Biotherapeutics Inc NWBO:OTCQB

RT Quote | Exchange | USD
Last | 3:41 PM EDT
1.35quote price arrow down-0.11 (-7.53%)
Volume
1,252,620
52 week range
0.68 - 2.51
Loading...
  • Open1.45
  • Day High1.50
  • Day Low1.35
  • Prev Close1.46
  • 52 Week High2.51
  • 52 Week High Date10/20/20
  • 52 Week Low0.68
  • 52 Week Low Date09/28/20

Key Stats

  • Market Cap1.178B
  • Shares Out872.44M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-9.51

KEY STATS

  • Open1.45
  • Day High1.50
  • Day Low1.35
  • Prev Close1.46
  • 52 Week High2.51
  • 52 Week High Date10/20/20
  • 52 Week Low0.68
  • 52 Week Low Date09/28/20
  • Market Cap1.178B
  • Shares Out872.44M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-9.51

RATIOS/PROFITABILITY

  • EPS (TTM)-0.60
  • P/E (TTM)-2.24
  • Fwd P/E (NTM)-1.32
  • EBITDA (MRQ)-102.997M
  • ROE (MRQ)-
  • Revenue (MRQ)1.37M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-34,505.68%
  • Debt To Equity (MRQ)-5.73%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Northwest Biotherapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to cover all solid tumor cancers in which the tumors can be surgically removed. It is on going Phase III trial for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is being studied in a 60-patient Phase I/II trial for all types of inoperable solid...
Linda Powers J.D.
Chairman
Marnix Bosch Ph.D.
Chief Technology Officer
Address
4800 Montgomery Ln Ste 800
Bethesda, MD
20814-3676
United States